Early Inhaled Glucocorticoid Therapy for Prevention of BPD: Assessment of Growth, History, and Pulmonary Function at 6 Months Corrected Age

Cynthia H. Cole(Tufts University), Ivan D. Frantz(Tufts Medical Center), Bhavesh Shah(Boston University), Soraya Abbassi(Boston University), Brenda L. MacKinnon(Boston University), Ted Colton(Boston University), Serkalem Demissie(MedStar Washington Hospital Center), Henry L. Dorkin(Boston Children's Hospital)
Pediatric Research
April 1, 1999
10.1203/00006450-199904020-01131
Cited by 3

Related Papers

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
|Nature Genetics|2011|2k
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation
|Thorax|2011|501
Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1993|458
Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs
|Human Molecular Genetics|1993|414
Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial
|Human Gene Therapy|2007|275